

University of Texas Rio Grande Valley

ScholarWorks @ UTRGV

School of Medicine Publications and
Presentations

School of Medicine

5-26-2021

Emerging issues in COVID-19 vaccination in Tropical Areas: Impact of the Immune Response against Helminths in Endemic Areas

Leonor Chacin-Bonilla

Nathalie Chacón-Fonseca

The University of Texas Rio Grande Valley

Alfonso J. Rodriguez-Morales

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub



Part of the [Public Health Commons](#)

Recommended Citation

Chacin-Bonilla, L., Chacón-Fonseca, N., & Rodriguez-Morales, A. J. (2021). Emerging issues in COVID-19 vaccination in Tropical Areas: Impact of the Immune Response against Helminths in Endemic Areas. *Travel medicine and infectious disease*, 102087. Advance online publication. <https://doi.org/10.1016/j.tmaid.2021.102087>

This Editorial is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu, william.flores01@utrgv.edu.




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

Emerging issues in COVID-19 vaccination in Tropical Areas: Impact of the Immune Response against Helminths in Endemic Areas

Leonor Chacin-Bonilla, Nathalie Chacón-Fonseca, Alfonso J. Rodriguez-Morales.



PII: S1477-8939(21)00128-9

DOI: <https://doi.org/10.1016/j.tmaid.2021.102087>

Reference: TMAID 102087

To appear in: *Travel Medicine and Infectious Disease*

Received Date: 20 May 2021

Accepted Date: 25 May 2021

Please cite this article as: Chacin-Bonilla L, Chacón-Fonseca N, Rodriguez-Morales. AJ, Emerging issues in COVID-19 vaccination in Tropical Areas: Impact of the Immune Response against Helminths in Endemic Areas *Travel Medicine and Infectious Disease*, <https://doi.org/10.1016/j.tmaid.2021.102087>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Elsevier Ltd. All rights reserved.

Editorial

Emerging issues in COVID-19 vaccination in Tropical Areas:

Impact of the Immune Response against Helminths in Endemic Areas

Leonor Chacin-Bonilla,^{1,*} Nathalie Chacón-Fonseca,² Alfonso J. Rodriguez-Morales.^{3,4,5,*}

¹Instituto de Investigaciones Clínicas, Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela.

²Department of Public Health, University of Texas Rio Grande Valley, Texas, United States of America.

³Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia. Associate Editor, TMAID.

⁴Universidad Científica del Sur, Lima, Perú.

⁵Universidad Privada Franz Tamayo (UNIFRANZ), Cochabamba, Bolivia.

*Corresponding authors. Email: leonorbonilla42@hotmail.com. Instituto de Investigaciones Clínicas, Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela.

Email: alfonso.rodriguez@uam.edu.co. Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia.

Keywords: COVID-19; SARS-CoV-2; helminth; immune response; vaccination.

Running title: COVID-19 vaccination in endemic helminth areas

The Coronavirus Disease 2019 (COVID-19) pandemic has affected over 165 million people and caused the death of 3.4 million worldwide (up to May 20, 2021) (<https://coronavirus.jhu.edu/map.html>), becoming a serious problem of global public health and the worst epidemic in the last century, after the pandemic 1918 influenza. Researchers worldwide are trying to find valuable drugs against the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Some of them focused as antivirals, others targeted in other ways (e.g. immunomodulation) to relieve the symptoms of the infected patients and help lower the death toll throughout the world. Unfortunately, there is a lack of effective drugs to manage COVID-19.

The hopeful and long-awaited development of vaccines and the approval of their use in humans is a fact. The time consuming that it will take to achieve herd immunity due to waiting for the availability and distribution of the vaccines is a reality in full swing and shows significant health inequalities. Vaccines with up to 95% of efficacy and effectiveness have been developed and approved by the Food and Drug Administration (FDA), USA. Worldwide, 1.55 billion vaccine doses have been administered (up to May 20, 2021) (<https://coronavirus.jhu.edu/map.html>). However, it is unknown if the development of post-infection immunity detected confers medium-long term protection and the importance of mucosal immunity to protect against infection is still a matter of concern [1]. The effectiveness of a vaccine depends in part on its ability to induce a defensive immune response. Nevertheless, severe reactions have been observed in vaccine development for other respiratory viruses, including SARS-CoV [2], probably produced by vaccine-induced antibodies that facilitate viral replication [3]; or by a predominant cellular Th2 response that accelerates the tissue damage produced by the disease

[4]. This reaction is of vital importance in the case of SARS-CoV-2 since the immune response in the form of a cytokine storm has been associated with severity [5].

A potential threat to patients with COVID-19 in helminths endemic areas (most of the tropical and subtropical areas of developing countries) is the systemic immunomodulatory effects of these parasites [6,7], through protein secretion [8] and by alteration of the intestinal microbiome [9], that may influence the severity of other infections. However, some authors consider this could be protective [10].

The possible implications of the immune-regulatory role of helminth intestinal infections in humans co-infected by SARS-CoV-2 and its effect on the viral disease outcome and COVID-19 vaccines efficacy must be considered carefully using them in endemic helminth areas, in terms of more studies to understand this relationship. The individuals infected with helminths before being affected by SARS-CoV-2 are responding to the parasite infections by a specific Th2 type innate and adaptive immune responses. The Th2 pattern cytokines predominate in long-term helminth infected individuals [11]. The co-infected host needs to control the viral infection by a robust Th1 type lung microenvironment in the initial stages of SARS-CoV-2 [12]. Helminths modified intestinal microbiome can modulate host immune response. It is not well-defined if the interaction between helminth-microbiota will promote susceptibility or protection in the lungs. However, the generation of a tolerogenic and anti-inflammatory environment could stimulate less immune response and more susceptibility to co-infections [13].

In helminth-infected individuals, the immunomodulation of the innate and adaptive immune response characterized by a deviation to a Th2 pattern could enhance viral replication of SARS-CoV-2 [11]. The significant case fatality rate caused by COVID-19, especially in certain countries, is produced by the uncontrolled innate immune response and destructive inflammation. Co-infections can modulate the host immunological outcome, and a range of responses can be observed during all clinical phases of COVID-19. The clinical resolution can be affected by different cofactors dependent on the virus, helminths, and the host, including their immunogenetic profile. Helminth co-infection might suppress the host immune responses and consequently could increase the severity of other infectious diseases, including COVID-19, and mitigate vaccine efficacy [4,5,11].

Helminthiases are among the most common infectious diseases in developing countries and are in a synergistic epidemic, called syndemic [14,15]; several pathogens could infect individuals, and COVID-19-helminth syndemic in these areas may be a common possibility, not yet studied and understood enough [16]. The effects of these pathogens on COVID-19 vaccines efficacy must be considered during the current deployment of the mass use of COVID-19 vaccines in these endemic regions, ideally before. For instance, *Schistosoma* infections decrease the efficacy of vaccines against tuberculosis or tetanus (toxoid) [17]; lower levels of INF- γ and higher levels of IL-10 and TGF- β in individuals co-infected with *Plasmodium*, *Ascaris lumbricoides*, and hookworms, as compared to those infected only by *Plasmodium*, have been observed [18]; experimentally, in mice, helminth infections reduced the quantity and quality of antibody responses to vaccination against seasonal influenza [19], and diminished the strong immunity induced by blood-stage antigens against *Plasmodium chabaudi* [20].

Before or concurrently with the mass use of COVID-19 vaccines in endemic helminth areas, public health strategic planning to decrease the helminth co-infection immunomodulatory effects must be studied. Massive deworming [6,15], or several boosts to induce a T-cell help response, and neutralizing antibodies as part of the adaptive immune response, such as immunomodulating therapies [21], human monoclonal antibody blocking SARS-CoV-2 infection [22], and the use of a specific adjuvant [23] have been suggested.

Schistosoma infection is correlated with increased transmission of HIV and deworming with decreased viral load, and improved CD4+ counts among HIV-infected individuals have been noted [15]. A single dose of 400 mg of albendazole before influenza immunization improved the immune response; the treated group had higher levels of total antibodies [24]. Deworming can decrease SARS-CoV-2 viral load and improve T cell CD8+ in the lung microenvironment [12]. Before implementing the COVID-19 vaccines, mass deworming could be a pharmacological intervention to improve anti-SARS-Cov-2 protection in helminth infected individuals, obviously requiring studies and confirmation yet.

Due to its immunomodulatory, antioxidant, anti-inflammatory, and neuroprotective effects, melatonin is a potential complement or therapeutic alternative to combat viral, bacterial, and parasitic infections [25,26]. We coincide with the suggestion that this hormone should be considered for studies at prophylactic use or treatment alone or in combination with other drugs for COVID-19 to understand its usefulness in this context [27]. It has been demonstrated that melatonin treatment enhances the efficiency of mice immunization against the Venezuelan

equine encephalomyelitis virus [28]. Therefore, the use of this hormone before implementing programs of COVID-19 vaccination in helminths endemic areas should be studied since this pharmacological intervention would improve the immune impact of vaccines. Melatonin would be cheap and be an adjuvant during COVID-19 vaccination.

The possible implications of the immune regulation caused by helminth intestinal infections in humans co-infected by SARS-CoV-2 are particularly worrisome in some countries of Latin America, such as is the case Venezuela, Honduras, Nicaragua, Peru, among others, since intestinal parasites constitute a serious and persistent public health problem in these nations. For example, along decades in Venezuela, it has been observed high rates of parasitic infection with one or more species, up to 92%, and rates of *Ascaris lumbricoides* and *Trichuris trichiura* up to 74.6% and 82.8%, respectively, in impoverished communities [29-32].

In the last two decades, the severe political, economic, and social crises in some countries have triggered an unprecedented increasing humanitarian crisis. That is especially the case of Venezuela. The rising trend of hyperinflation and food shortages have enhanced poverty and malnutrition rates; 96% of households are in poverty and 79% in extreme indigence. The malnutrition rate in children under five years of age from Venezuela is 8% [33]. This sequence of events and the collapse of health systems and public services foster the prevalence, transmission, and dynamic epidemiology of infectious agents. An increase in the prevalence of multiple infectious diseases, re-emergence of controlled illnesses such as tuberculosis, cholera, measles, diphtheria, malaria, yellow fever, and multiple outbreaks have been observed in

Venezuela the last two decades [34]. The whole immune balance status attributable to the immune interaction between host and pathogens must be defined in the current scenario.

This complex epidemiological, sanitary, and poverty picture combined with the powerful transmissibility and eventual severity of the infection by SARS-CoV-2 indicate the significant risk of such populations suffering a more devastating impact of COVID-19 than people from other regions. According to family wealth, education, and ethnic group, substantial inequalities in the prevalence of infection have been revealed in developing and industrialized countries [35,36]. COVID-19 pandemic is beating Latin American countries with intensity. It is more complex at the poorest and disadvantaged groups [35]. Venezuela is currently the poorest country in this area and is ranked second in extreme poverty worldwide, only surpassed by Nigeria in Africa [33].

On the other hand, the several strategies that have been proposed to diminish helminths impact over viral vaccination are not feasible in Venezuela due to its current economic collapse. The situation in this country is incredibly distressing due to the collapse of the health systems, the scarcity of medicines and care policies for seniors and the impoverished. It is conceivable that COVID-19 morbidity and mortality in Venezuela could be high, and vaccines' immune impact is affected. In the current scenario of this country, COVID-19-helminth syndemic may be a joint likelihood, and the whole immune balance attributable to the immune interaction between host and pathogens must be resolved [6,10,37,38].

The possible implications of the immune-regulation triggered by helminths in humans co-

infected by SARS-CoV-2 and its effects on the viral disease outcome and vaccination effectiveness raise high expectations and questions that need to be determined and open new avenues of investigation, particularly in tropical countries [6,10,37-40]. In conclusion, the implications of the immunomodulation effect of helminths in endemic areas must be considered in the context of COVID-19 mass vaccination.

Conflicts of interest

None.

References

1. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581:465-69. Available from: <https://doi.org/10.1038/s41586-020-2196-x>
2. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. *J Virol*. 2011; 85(23):12201-15.
3. Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. *Biochem Biophys Res Commun*. 2014;451(2):208-14.
4. Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of nonpharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. 2020. Available from: <https://doi.org/10.25561/77482>
5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. Available from: [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)

6. Bradbury RS, Piedrafita D, Greenhill A, Mahanty S. Will helminth co-infection modulate COVID-19 severity in endemic regions? *Nat Rev Immunol*. 2020;20:342. Available from: <https://doi.org/10.1038/s41577-020-0330-5>
7. Abdoli A. Helminths and COVID-19 co-infections: A neglected critical challenge. *ACS Pharmacol Transl Sci*. 2020;3(5):1039-41.
8. Harris NL, Loke P. Recent advances in type-2-cell-mediated immunity: Insights from helminth infection. *Immunity*. 2017;47(6):1024-36.
9. Brosschot TP, Reynolds LA. The impact of a helminth-modified microbiome on host immunity review-article. *Mucosal Immunol*. 2018;11(4):1039-46.
10. Hays R, Pierce D, Giacomini P, Loukas A, Bourke P, McDermott R. Helminth co-infection and covid-19: An alternate hypothesis. *PLoS Negl Trop Dis*. 2020;14(8): e0008628. <https://doi.org/10.1371/journal.pntd.0008628>
11. Zakeri A, Hansen EP, Andersen SD, Williams AR, Nejsum P. Immunomodulation by helminths: Intracellular pathways and extracellular vesicles. *Front Immunol*. 2018; 9:2349. <https://doi.org/10.3389/fimmu.2018.02349>
12. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. *Nat Med* 2020; 26: 842-4. Available from: <https://doi.org/10.1038/s41591-020-0901-9>
13. McFarlane AJ, McSorley HJ, Davidson DJ, Fitch PM, Errington C, Mackenzie KJ, et al. Enteric helminth-induced type I interferon signaling protects against pulmonary virus infection through interaction with the microbiota. *J Allergy Clin Immunol*. 2017;140(4):1068-78.e6. Available from: <https://doi.org/10.1016/j.jaci.2017.01.016>
14. Rodriguez C. The global helminth belt and Covid-19 : the new eosinophilic link. 2020. Available from: <https://www.qeios.com/read/IWKQH9.2>
15. Gutman JR, Lucchi NW, Cantey PT, Steinhardt LC, Samuels AM, Kamb ML, et al. malaria and parasitic neglected tropical diseases: Potential syndemics with COVID-19?. *Am J Trop Med Hyg*. 2020;103(2):572-77.
16. Taylor-Robinson DC, Maayan N, Donegan S, Chaplin M, Garner P. Public health deworming programmes

- for soil-transmitted helminths in children living in endemic areas. *Cochrane Database Syst. Rev.* 2019; 9(9): CD000371. Available from: <https://doi.org/10.1002/14651858>
17. van Riet E, Hartgers FC, Yazdanbakhsh M. Chronic helminth infections induce immunomodulation: Consequences and mechanisms. *Immunobiology.* 2007;212(6):475-90.
 18. Bwanika R, Kato CD, Welishe J, Mwandah DC. Cytokine profiles among patients co-infected with *Plasmodium falciparum* malaria and soil borne helminths attending Kampala International University Teaching Hospital, in Uganda. *Allergy, Asthma Clin Immunol.* 2018;14(10):1-9.
 19. Hartmann W, Brunn ML, Stetter N, Gagliani N, Muscate F, Stanelle-Bertram S, et al. Helminth infections suppress the efficacy of vaccination against seasonal influenza. *Cell Rep.* 2019;29:2243-56.e4. Available from: <https://doi.org/10.1016/j.celrep.2019.10.051>
 20. Su Z, Segura M, Stevenson MM. Reduced protective efficacy of a blood-stage malaria vaccine by concurrent nematode infection. *Infect Immun.* 2006; 74(4):2138-44.
 21. Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? *Lancet Rheumatol.* 2020;2:e428-36. Available from: [https://doi.org/10.1016/S2665-9913\(20\)30120-X](https://doi.org/10.1016/S2665-9913(20)30120-X)
 22. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat Commun.* 2020;11(2251). Available from: <https://doi.org/10.1038/s41467-020-16256-y>
 23. Moreau E, Chauvin A. Immunity against helminths: Interactions with the host and the intercurrent infections. *J Biomed Biotechnol.* 2010; 2010: 428593. Available from: <https://doi.org/10.1155/2010/428593>
 24. Brückner S, Agnandji ST, Berberich S, Bache E, Fernandes JF, Schweiger B, et al. Effect of antihelminthic treatment on vaccine immunogenicity to a seasonal influenza vaccine in primary school children in Gabon: A randomized placebo-controlled trial, *PLoS Negl Trop Dis.* 2015; 9(6): e0003891. Available from: <https://doi.org/10.1371/journal.pntd.0003768>
 25. Vielma JR, Bonilla E, Chacin-Bonilla L, Mora M, Medina-Leendertz S, Bravo Y. Effects of melatonin on oxidative stress, and resistance to bacterial, parasitic, and viral infections: A review. *Acta Trop.*

- 2014;137:31-8. Available from:
<https://doi.org/10.1016/j.actatropica.2014.04.021>
26. Chacin-Bonilla L, Vielma JR, Bonilla E. Should melatonin be considered a complementary or alternative therapy against parasitic infections? *Epidemiol Open Access*. 2014;4(4).
Available from: <https://dx.doi.org/10.4172/2161-1165.1000e117>
27. Reiter RJ, Abreu-Gonzalez P, Marik PE, Dominguez-Rodriguez A. Therapeutic algorithm for use of melatonin in patients with COVID-19. *Front Med*. 2020;7:226. Available from:
<https://doi.org/10.3389/fmed.2020.00226>
28. Negrette B, Bonilla E, Valero N, Garcia Tamayo J., Chacin-Bonilla L, Medina-Leendertz S, et al. Melatonin treatment enhances the efficiency of mice immunization with Venezuelan equine encephalomyelitis virus TC-83. *Neurochem Res*. 2001;26:767-70. Available from:
<https://doi.org/10.1023/A:1011645400123>
29. Chacin-Bonilla L, Dikdan Y. Prevalencia de *Entamoeba histolytica* y otros parásitos intestinales en una comunidad suburbana de Maracaibo. *Invest Clin*. 1981; 22(4):185-203
30. Chacin-Bonilla L, Dikdan Y, Guanipa N, Villalobos R. Prevalencia de *Entamoeba histolytica* y otros parásitos intestinales en un un barrio del municipio Mara, estado Zulia, Venezuela. *Invest Clin*.1990; 31(1):3-15.
31. Chacin-Bonilla L, Sanchez-Chavez Y. Intestinal parasitic infections, with special emphasis on cryptosporidiosis, in Amerindians from Western Venezuela. *Am J Trop Med Hyg* 2000; 62(3):347-52.
32. Chacín-Bonilla L, Barrios F, Sanchez Y. Epidemiology of *Cyclospora cayetanensis* infection in San Carlos Island, Venezuela: strong association between socio-economic status and infection. *Trans R Soc Trop Med Hyg*. 2007;101(10):1018-24.
33. Universidad Catolica Andres Bello (UCAB). Encuesta Nacional de Condiciones de Vida (ENCOVI) 2019-2020. Available from: <https://www.proyectoencovi.com/informe-interactivo-2019>
34. Chacin-Bonilla L. Perfil epidemiológico de las enfermedades infecciosas en Venezuela. *Invest Clin*. 2017;58 (2):103-5. Available from: <https://sites.google.com/site/revistainvestiga2017/home/invest-clin-58-2-2017>
35. Horta BL, Silveira MF, Barros AJD, Barros FC, Hartwig FP, Dias MS, et al. Prevalence of antibodies against SARS-CoV-2 according to socioeconomic and ethnic status in a nationwide Brazilian survey. *Rev*

- Panam Salud. 2020; 44: e135. Available from: <https://doi.org/10.26633/RPSP.2020.135>
36. de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. *Lancet Infect Dis.* 2020; 20(9):1034-42.
 37. Paniz-Mondolfi A, Ramírez JD, Delgado-Noguera LA, Rodríguez-Morales AJ, Sordillo EM. COVID-19 and helminth infection: beyond the Th1/Th2 paradigm. *PLoS Negl Trop Dis.* 2021 (accepted, in press # PNTD-D-20-01994R2)
 38. Siles-Lucas M, González-Miguel J, Geller R, Sanjuan R, Pérez-Arévalo J, Martínez-Moreno Á. Potential Influence of Helminth Molecules on COVID-19 Pathology. *Trends Parasitol.* 2021;37(1):11-14.
 39. de Freitas E Silva R, Pitzurra R. What are the factors influencing the COVID-19 outbreak in Latin America? *Travel Med Infect Dis.* 2020;35:101667. doi: 10.1016/j.tmaid.2020.101667.
 40. Eldanasory OA, Rabaan AA, Al-Tawfiq JA. Can influenza vaccine modify COVID-19 clinical course? *Travel Med Infect Dis.* 2020;37:101872. doi: 10.1016/j.tmaid.2020.101872.